| Schedule of segment information |
| | | | | | | | | | | | | | | For the Years ended September 30, 2025 | | | Diversified | | | | | | | | | | | | Pharmaceutical | | | | | | | | | | | and Allied | | | | | Insurance | | | | | | Products | | AI Solutions | | Business | | Total | Revenue | | $ | 23,591,893 | | | 3,362,732 | | | 10,964,800 | | | 37,919,425 | Cost of revenue | | | 20,896,423 | | | 1,868,683 | | | 8,842,860 | | | 31,607,966 | Gross profit | | $ | 2,695,470 | | | 1,494,049 | | | 2,121,940 | | | 6,311,459 | Depreciation and amortization | | $ | 1,393,233 | | | 66,913 | | | 3,044 | | | 1,463,190 | Capital expenditures | | $ | 2,030,607 | | | 141,390 | | | 14,907 | | | 2,186,904 |
| | | | | | | | | | | | | | | For the Years ended September 30, 2024 | | | Diversified | | | | | | | | | | | Pharmaceutical | | | | | | | | | | | and Allied | | | | | Insurance | | | | | | Products | | AI Solutions | | Business | | Total | Revenue | | $ | 25,097,951 | | $ | — | | | — | | $ | 25,097,951 | Cost of revenue | | | 20,983,196 | | | — | | | — | | | 20,983,196 | Gross profit | | $ | 4,114,755 | | $ | — | | | — | | $ | 4,114,755 | Depreciation and amortization | | $ | 1,237,230 | | $ | — | | | — | | $ | 1,237,230 | Capital expenditures | | $ | 3,931,471 | | $ | — | | | — | | $ | 3,931,471 |
| | | | | | | | | | | | | | | For the Years ended September 30, 2023 | | | Diversified | | | | | | | | | | | | Pharmaceutical | | | | | | | | | | | and Allied | | | | | Insurance | | | | | | Products Diversified | | AI Solutions | | Business | | Total | Revenue | | $ | 46,471,478 | | $ | — | | | — | | $ | 46,471,478 | Cost of revenue | | | 44,719,984 | | | — | | | — | | | 44,719,984 | Gross profit | | $ | 1,751,494 | | $ | — | | | — | | $ | 1,751,494 | Depreciation and amortization | | $ | 1,143,064 | | $ | — | | | — | | $ | 1,143,064 | Capital expenditures | | $ | 3,714,089 | | $ | — | | | — | | $ | 3,714,089 |
|